# A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

> **NCT05972629** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 32 (estimated)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** SAR444836

## Key facts

- **NCT ID:** NCT05972629
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-07
- **Primary completion:** 2030-04-02
- **Final completion:** 2030-04-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972629, "A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05972629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*